12 October 2018
Bionure, a biotech company specialized in neuroprotection member of CataloniaBio & HealthTech, announces the appointment of Dr. Laurent Nguyen as the new CEO and strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist.
Nguyen is doctor in Medicine and has a solid experience in the pharmaceutical industry at Hoechst-Roussel, Merck, F. Hoffmann-La Roche and Pierre Fabre. He then moved to the biotech sector where he became CEO of a French academic spin-off that he developed into a publicly traded clinical biotech company.
The ongoing Phase I clinical trial of its neuroprotective and remyelinating compound ...
11 October 2018
Alta Life Sciences, the fund led by Guy Nohra, Montserrat Vendrell, Miguel Valls and Scott Moonly and a CataloniaBio & HealthTech member, has led a €3-million round of investment in Mediktor. The round also included Dutch fund Castel Capital and French Naos Capital Partners.
Mediktor is a symptom assessment software launched as a free app in 2014. Over this time, it has done more than 2 million evaluations of symptoms in 150 countries and created a database that can recognise roughly 750 diseases, covering 90% of the cases seen in emergency and primary care. Recently, Mediktor has collaborated with Hospital ...
11 October 2018
Institut Marquès, a global benchmark in gynaecology, obstetrics and assisted reproduction with its main headquarters in Barcelona, has opened a new facility in the modern Beacon Court medical services centre in Sandyford (Ireland). The city of Sandyford is well connected to the centre of Dublin, where the clinic has a surgery for medical appointments.
Created by generations of gynaecologists, InstitutMarquès became a member of CataloniaBio & HealthTech in 2018 and has a scientific division led by Dr Alex Garcia-Faura that is working on several lines of research.
The centre has the latest technology, such as the most modern genetic analysis ...
10 October 2018
Pangaea Oncology, associada a CataloniaBio & HealthTech, ha nomenat Alejandro García Moncayo nou director general corporatiu de la companyia.
García Moncayo és llicenciat en Administració i Direcció d'Empreses per la Universitat Pompeu Fabra i ha cursat un Programa de Desenvolupament Directiu (PDD) a Iese i un màster de Finances corporatives a Esade. Amb més d'11 anys d'experiencia, ha treballat en empreses com AB-Biotics o Renta Corporación. El directiu qualifica el projecte "d'ambiciós i molt interessant".
Fundada a Barcelona el 2007, Pangea Oncology és una companyia de serveis mèdics centrada en l'oncologia de precisió a través de la divisió d'atenció ...
8 October 2018
CataloniaBio & HealthTech has launched a Regulatory Affairs Workgroup (WG) in order to help members stay up-to-date on regulatory changes and implementations, boost institutional relations with agencies, foster the transfer of expertise and know-how to start-ups, and give companies the chance to express their concerns, propose activities and participate in carrying them out.
This WG is coordinated by Lidia Cánovas (Asphalion) and Lluís Chico (NEOS Surgery), both of which are board members, with support from Melqui Calzado (secretary general). "We hope members will participate actively to make this a quality WG that is useful to all," highlighted the coordinating ...
26 September 2018
Ysios Capital, venture capital firm specialised in life sciences and member of CataloniaBio & HealthTech, announced that it has appointed Guillem Laporta as Principal and Claudia D’Augusta and Lance Berman as new Venture Partners to strengthen the strategic area and analysis, as well as international projection.
Laporta started his career at Caixa Capital Risc. Since 2013 was Associate at Edmond de Rothschild group (now Andera Partners).
D'Augusta has an extensive experience in the financial management of biotechnology companies and currently is General Manager at TiGenix. Prior to joining Ysios, Berman was CMO and Senior Vice President at Relypsa in ...
26 September 2018
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases member of CataloniaBio & HealthTech, today announces the completion of a Series B funding round of €21.3 million, the most important in the Catalan biotechnology sector so far this year.
The funding round was led by Fund+, joined by SRIW, SFPI-FPIM and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi Ventures, Caixa Capital Risc and HealthEquity).
“The proceeds of the round will allow the company to demonstrate the potential of MIN-102 in new indications,” ...
19 September 2018
4 Clinical Trials and Anagram announces their merge with the aim to be the first CRO that integrates Imaging Core Lab services with clinical trial management in Spain.
4 Clinical Trials was born in 2016 to provide support to the clinical reach world from different angles and works in partnership with IEC, a imaging CRO that provides integrated image management solutions for clinical trials.
On the other hand, Anagram, founded in 1998, has a solid track record in supporting clinical trials, both with investigational products and medical devices. With deep experience in cardiovascular and stroke, among other therapeutic areas, Anagram ...
19 September 2018
Avinent and the Institute for Bioengineering of Catalonia (IBEC), members of CataloniaBio & HealthTech, have managed to print 3D prostheses that are incorporated into the body and become their own after about three years.
It is a disruptive innovation in the fields of regenerative medicine and dentistry that will allow to improve treatments for several diseases.
The research project has been carried out for now on a chicken embryo membrane and mice. The 3D bioprinter that is used is one of the few providing the level of precision and features required in regenerative medicine in southern Europe.
Avinent, managed by ...
19 September 2018
Spherium Biomed, specialized in developing biomedical products developed in academia and a member of CataloniaBio & HealthTech, has presented the positive results of the Phase II clinical trial of an innovative treatment for atopic dermatitis at the European Academy of Dermatology and Venerology Congress in Paris.
This is Spherium’s fourth pharmaceutical product in clinical stages and the third to pass the Phase II efficacy studies. The Cyclatop global market is in the 6 billion dollar range worldwide, with an estimated target population of 54 million people for the next decade.
According Luis Ruiz-Ávila, CEO of the biopharmaceutical company: "The next ...